HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia

European Journal of Cancer

Volumn 38, Issue 4, 2002, Pages 602-608

  St'astny M ^a   Plocova D ^b   Etrych, T ^b   Ulbrich, K ^b   Ihova B ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

^b INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

Author keywords

Biodegradable HPMA hydrogels; Cyclosporines; Doxorubicin; Multidrug resistance; N (2 Hydroxypropyl)methacrylamide; P Glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN A; CYTOSTATIC AGENT; DOXORUBICIN; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG RELEASE; DRUG SENSITIVITY; HYDROGEL; LEUKEMIA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; DOXORUBICIN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, NEOPLASM; HYDROGELS; LEUKEMIA, B-CELL; MICE; MICE, INBRED BALB C; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0036185419     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(01)00421-X     Document Type: Article

References (25)

1. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles
2. Novel biodegradable hydrogels prepared using the divinyliccrosslinking agent N,O-dimethacryloylhydroxylamine. 1. Synthesis and characterization of rates of gel degradation, and rate of release of model drugs, in vitro and in vivo
3. HPMA-based biodegradable hydrogels containing different forms of doxorubicin. Antitumor effects and biocompatibility
4. P-glycoprotein: Multidrug resistance and a superfamily of membrane-associated proteins
5. How cancer cells evade chemotherapy: Sixteenth Richard and Hinda Rosenthal Foundation Award lecture
6. The role of passive transbilayer movement in multidrug resistance and its modulation
7. Flow cytometric analyses of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918
8. P-Glycoprotein expression is a marker for chemotherapy resistance and prognosis in advanced ovarian cancer
9. Clinical approach to circumvention of multidrug resistance in refractory leukaemic patients: Association of cyclosporine A with etoposide
10. PSC833: Initial clinical results in refractory ovarian cancer patients
11. Myeloid and lymphoid cell alterations in normal mice exposed to chemotherapy with doxorubicin and/or the multidrug-resistance reversing agent SDZ PSC 833
12. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp)
13. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays
14. Poly[N-(2-hydroxypropyl)methacrylamide]. IV. Heterogeneous polymerization
15. Synthesis of novel hydrolytically degradable hydrogels for controlled drug release
16. Nano and microparticles as controlled drug delivery devices
17. Biodegradable polymeric nanoparticles as drug delivery devices
18. Protein delivery from biodegradable microspheres
19. Hydrogels in pharmaceutical formulations
20. Reactive copolymers of N-(2-hydroxypropyl) methacrylamide with N-methacryloylated derivatives of L-leucine and L-phenylalanine
21. Antibody-directed affinity therapy applied to the immune system: In vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody
22. A possibility to overcome Pgp-mediated multidrug resistence by antibody-targeted drugs conjugated to HPMA-copolymer carrier
23. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy
24. P-Glycoprotein protects leukemia cells from caspase-dependent, but not caspase-independent cell death